Benign Hematologic Disorders

2016 ◽  
pp. 399-414
Author(s):  
Naseema Gangat
Keyword(s):  
Menstrual Cycle ◽  
Luteinizing Hormone ◽  
Corpus Luteum ◽  
Hormone Level ◽  
Ovarian Follicle ◽  
Follicle Stimulating Hormone ◽  
Luteinizing Hormone Level ◽  
Hormone Release ◽  
Hematologic Disorders ◽  
Mature Follicle

The menstrual cycle is composed of the follicular (proliferative), periovulatory, and luteal (secretory) phases. At periovulation, the mature follicle triggers a surge in luteinizing hormone level, causing ovum release and stimulating the residual ovarian follicle to transform into a corpus luteum. Circulating estrogen and progestin levels increase. A thickened, enriched endometrium develops owing to progestin secretion from the corpus luteum. Without fertilization, the corpus luteum atrophies, estrogen and progestin levels decline, follicle-stimulating hormone release is stimulated, and the endometrium sloughs.

scholarly journals Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome

2017 ◽  
Vol 30 (3) ◽  
pp. 138-141
Author(s):  
Olha Horbatiuk ◽  
Alla Binkovska ◽  
Olena Herych ◽  
Andriy Ropotan ◽  
Natalia Zhylko ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Luteinizing Hormone ◽  
Premenstrual Syndrome ◽  
Hormone Level ◽  
Clinical Symptoms ◽  
Progesterone Level ◽  
Laboratory Research ◽  
Luteinizing Hormone Level ◽  
Natural Structure ◽  
Micronized Progesterone

Abstract In this study, we carried out the clinical and laboratory research of severe PMS (premenstrual syndrome) treatment in premenopausal age women. Herein, 37 women were examined and observed before the beginning of treatment and three months after it. Medication containing micronized progesterone was used for treatment (sublingually, 100 mg from 11 to 25 days of menstrual cycle). After three months of micronized progesterone treatment, 86.5% of all women-participants of the study were observed to have full regression of clinical symptoms, while 13.5% of all patients were observed to have decrease in clinical symptoms of severe PMS. Moreover, hormonal research results revealed significant (1.3 times) decrease in LH (Luteinizing hormone) level and (1.3 times) increase in progesterone level after three months of treatment (р<0.05). The high bio-accessibility of the medication and its natural structure made it possible to decrease the dose and avoid risks of hepatotoxicity.

Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day

2015 ◽  
Vol 53 (7) ◽  
Author(s):  
Sarah Johnson ◽  
Sarah Weddell ◽  
Sonya Godbert ◽  
Guenter Freundl ◽  
Judith Roos ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Hormone Level ◽  
Ovarian Follicle ◽  
Reproductive Hormone ◽  
Fertility Status ◽  
Daily Urine ◽  
Follicle Size ◽  
Status Information ◽  
Progesterone Metabolite ◽  
Level Analysis

AbstractUrinary hormone level analysis provides valuable fertility status information; however, previous studies have not referenced levels to the ovulation day, or have used outdated methods. This study aimed to produce reproductive hormone ranges referenced to ovulation day determined by ultrasound.Women aged 18–40 years (no reported infertility) collected daily urine samples for one complete menstrual cycle. Urinary luteinising hormone (LH), estrone-3-glucuronide (E3G, an estradiol metabolite), follicle stimulating hormone (FSH) and pregnanediol-3-glucuronide (P3G, a progesterone metabolite) were measured using previously validated assays. Volunteers underwent trans-vaginal ultrasound every 2 days until the dominant ovarian follicle size reached 16 mm, when daily scans were performed until ovulation was observed. Data were analysed to create hormone ranges referenced to the day of objective ovulation as determined by ultrasound.In 40 volunteers, mean age 28.9 years, urinary LH surge always preceded ovulation with a mean of 0.81 days; thus LH is an excellent assay-independent predictor of ovulation. The timing of peak LH was assay-dependent and could be post-ovulatory; therefore should no longer be used to predict/determine ovulation. Urinary P3G rose from baseline after ovulation in all volunteers, peaking a median of 7.5 days following ovulation. Median urinary peak E3G and FSH levels occurred 0.5 days prior to ovulation. A persistent rise in urinary E3G was observed from approximately 3 days pre- until 5 days post-ovulation.This study provides reproductive hormone ranges referenced to the actual day of ovulation as determined by ultrasound, to facilitate examination of menstrual cycle endocrinology.

Sign in / Sign up

Export Citation Format

Share Document